Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 55% Improvement Relative Risk c19hcq.org Membrillo de Novales et al. HCQ LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 166 patients in Spain Lower mortality with HCQ (p=0.002) Membrillo de Novales et al., Preprints 2020, 202.., doi:10.20944/preprints202005.0057.v1 Favors HCQ Favors control
Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
Membrillo de Novales et al., Preprints 2020, 2020050057, doi:10.20944/preprints202005.0057.v1 (Preprint)
Membrillo de Novales et al., Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational.., Preprints 2020, 2020050057, doi:10.20944/preprints202005.0057.v1 (Preprint)
May 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
166 patients hospitalised with COVID-19, HCQ increased survival 1.4 - 1.8 times when patients admitted in early stages. Early is relative to hospital admission here - all patients were in relatively serious condition.
risk of death, 55.1% lower, RR 0.45, p = 0.002, treatment 27 of 123 (22.0%), control 21 of 43 (48.8%), NNT 3.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Membrillo de Novales et al., 5 May 2020, retrospective, Spain, preprint, 19 authors, average treatment delay 7.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 9 May 2020 doi:10.20944/preprints202005.0057.v2 Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study. Membrillo FJ1,2**, Ramírez-Olivencia G*1,7, Estébanez M*1,7, de Dios B*1,7, Herrero MD*1,7, Mata T*1,7, Borobia AM3, Gutierrez C4, Simón M5, Ochoa A6, Martinez Y1, Aguirre A8 , Alcántara F9, Fernández P9, López E8, Valle P3, Campos S6, Navarro M7, Ballester E1, on behalf of the COVID19 Central Defense Hospital “Gómez Ulla” Team (annex 1) 1: CRBN & Infectious Diseases Unit. HLIU. Central Defense Hospital “Gómez Ulla”, Madrid, Spain. 2: Infectious Diseases Unit. Central Defense Hospital “Gómez Ulla”, Madrid, Spain. 3: Clinical Pharmacology Department. La Paz Hospital, Madrid, Spain. 4: Preventive Medicine Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain. 5: Microbiology Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain. 6: Pneumology Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain. 7: Internal Medicine Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain. 8: Ophthalmology Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain. 9: Dermatology Department. Central Defense Hospital “Gómez Ulla”, Madrid, Spain. *contributed equally **corresponding author. Francisco Javier Membrillo de Novales. CRBN & Infectious Diseases Unit. Central Defense Hospital “Gómez Ulla”. Glorieta del Ejército, s/n, 28047 Madrid (Spain). fmemnov@oc.mde.es © 2020 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 9 May 2020 doi:10.20944/preprints202005.0057.v2 Summary: Hydroxychloroquine has shown in vitro activity against SARS-CoV-2. Here we present an observational study. We analysed data from 164 patients admitted to our hospital diagnosed with COVID-19. Hydroxychloroquine treatment was associated with an increase in the mean cumulative survival. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 9 May 2020 doi:10.20944/preprints202005.0057.v2 ABSTRACT Background: Although no specific treatment for COVID 19 has been proven effective yet, some drugs with in vitro potential against SARS-CoV-2 virus have been proposed for clinical use. Hydroxychloroquine has in vitro anti-viral and immunomodulatory activity, but there is no current clinical evidence of its effectiveness on the outcome of the disease. Methods: We enrolled all 18-85 years old inpatients from Central Defense Hospital, Madrid, Spain, who were hospitalised due to COVID-19 and had a definitive outcome (either dead or discharged). We used a statistical survival analysis. Results: We analysed 220 medical records. 166 patients met the inclusion criteria. 48,8 % of patients not treated with HCQ died, versus 22% in the group of hydroxychloroquine (p=0,002). According to clinical picture at admission, hydroxychloroquine increased the mean cumulative survival in all groups from 1,4 to 1,8 times. This difference was statistically significant in the mild group. Conclusions: in a cohort of 166 patients between 18 to 85 years hospitalised with COVID-19, hydroxychloroquine treatment with an initial loading dose of 800mg improved patient survival when admitted in early stages of the disease. There was a non-statistically significant trend towards survival in all groups, which will need to be clarified in subsequent studies. Type of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit